{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:01:00Z","timestamp":1784919660296,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.leukres.2017.01.008","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T04:24:01Z","timestamp":1483676641000},"page":"6-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study"],"prefix":"10.1016","volume":"55","author":[{"given":"Aline S.B.","family":"Perazzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Salvador R.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera L.P.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lourdes L.F.","family":"Chauffaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.008_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.hoc.2009.04.008","article-title":"The myelodysplastic syndromes","volume":"23","author":"Nguyen","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.leukres.2017.01.008_bib0015","first-page":"583","article-title":"Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment","volume":"91","author":"Barrett","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.01.008_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2141.2009.07921.x","article-title":"Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes","volume":"148","author":"Alfinito","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2017.01.008_bib0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database","volume":"38","author":"Wilson","year":"2014","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.leukres.2017.01.008_bib0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2017.01.008_bib0035","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00277-015-2363-6","article-title":"Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab","volume":"94","author":"Simonetta","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.01.008_bib0040","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2005.12.021","article-title":"Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells","volume":"30","author":"Maratheftis","year":"2006","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2017.01.008_bib0045","first-page":"427","article-title":"Successful treatment with cyclosporine for myelodysplastic syndrome with erythroid hypoplasia following rheumatoid arthritis","volume":"51","author":"Tsuji","year":"2010","journal-title":"Rinsho Ketsueki."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1756-185X.2012.01704.x","article-title":"Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis","volume":"15","author":"Kim","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.leukres.2017.01.008_bib0055","first-page":"150","article-title":"Immunological abnormalities in myelodysplastic syndromes","volume":"33","author":"Hamblin","year":"1996","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0060","first-page":"22","article-title":"Inflammatory rheumatologic disorders in patients with myelodysplastic syndromes: a cross-sectional study","volume":"9","author":"Mobini","year":"2015","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.leukres.2017.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.exphem.2007.09.007","article-title":"Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome","volume":"35","author":"Kerbauy","year":"2007","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2017.01.008_bib0070","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/blood-2005-04-1543","article-title":"Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome","volume":"106","author":"Sternberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.008_bib0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3324\/haematol.13612","article-title":"Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome","volume":"94","author":"Chamuleau","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.01.008_bib0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2017.01.008_bib0085","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2017.01.008_bib0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.leukres.2013.01.019","article-title":"IL10 inversely correlates with the percentage of CD8\u207a cells in MDS patients","volume":"37","author":"Lopes","year":"2013","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2017.01.008_bib0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/ejh.12577","article-title":"Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome","volume":"96","author":"Kasamatsu","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2017.01.008_bib0100","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.23785","article-title":"The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"113","author":"Tsimberidou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.01.008_bib0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4\u2009+\u2009CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.008_bib0110","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/leu.2008.333","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.008_bib0115","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.4049\/jimmunol.181.3.1673","article-title":"IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression","volume":"181","author":"Fragale","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2017.01.008_bib0120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/ard.2003.012948","article-title":"Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression","volume":"63","author":"Giannouli","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.leukres.2017.01.008_bib0125","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.leukres.2009.03.008","article-title":"The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome","volume":"33","author":"Pinheiro","year":"2009","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/107999002753452647","article-title":"Affabris E. IRF-1 as a negative regulator of cell proliferation","volume":"22","author":"Romeo","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.leukres.2017.01.008_bib0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/scbi.2000.0310","article-title":"The interferon regulatory factors and oncogenesis","volume":"10","author":"Tanaka","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.leukres.2017.01.008_bib0140","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.01.008_bib0145","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.008_bib0150","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.008_bib0155","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.008_bib0160","doi-asserted-by":"crossref","DOI":"10.1002\/0471142956.cy0911s27","article-title":"Flow cytometric analysis of cell division by dye dilution","author":"Lyons","year":"2004","journal-title":"Curr. Protoc. Cytom."},{"key":"10.1016\/j.leukres.2017.01.008_bib0165","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2017.01.008_bib0170","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ijc.25430","article-title":"Cancer inflammation and regulatory T cells","volume":"127","author":"Erdman","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2017.01.008_bib0175","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","article-title":"Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome","volume":"189","author":"Mailloux","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc703","article-title":"Helicobacter pylori and gastrointestinal tract adenocarcinomas","volume":"2","author":"Peek","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2017.01.008_bib0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.20020556","article-title":"Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis","volume":"196","author":"Kullberg","year":"2002","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.leukres.2017.01.008_bib0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.leukres.2017.01.008_bib0195","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4049\/jimmunol.0903627","article-title":"Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms","volume":"185","author":"Oliaro","year":"2010","journal-title":"J. Immunol."},{"issue":"5819","key":"10.1016\/j.leukres.2017.01.008_bib0205","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1126\/science.1139393","article-title":"Asymmetric T lymphocyte division in the initiation of adaptive immune responses","volume":"315","author":"Chang","year":"2007","journal-title":"Science"},{"issue":"6066","key":"10.1016\/j.leukres.2017.01.008_bib0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1126\/science.1213495","article-title":"Asymmetric B cell division in the germinal center reaction","volume":"335","author":"Barnett","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.leukres.2017.01.008_bib0215","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fimmu.2013.00264","article-title":"Asymmetry of cell division in CFSE-based lymphocyte proliferation analysis","volume":"4","author":"Bocharov","year":"2013","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2017.01.008_bib0220","first-page":"509","article-title":"Identification and analysis of IRF-1 binding protein","volume":"71","author":"Kondo","year":"1996","journal-title":"Hokkaido Igaku Zasshi"},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0225","doi-asserted-by":"crossref","first-page":"e1040217","DOI":"10.1080\/2162402X.2015.1040217","article-title":"(Compl)Ex-Th17-Treg cell inter-relationship","volume":"5","author":"Obermajer","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.leukres.2017.01.008_bib0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cei.12668","article-title":"IL-1R1 is expressed on both Helios(+) and Helios(\u2212) FoxP3(+) CD4(+) T cells in the rheumatic joint","volume":"182","author":"M\u00fcller","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.leukres.2017.01.008_bib0235","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nri3464","article-title":"The plasticity and stability of regulatory T cells","volume":"13","author":"Sakaguchi","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.leukres.2017.01.008_bib0240","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/nm1312","article-title":"Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.leukres.2017.01.008_bib0245","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4049\/jimmunol.161.3.1156","article-title":"Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement","volume":"161","author":"Punch","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2017.01.008_bib0250","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/leu.2011.251","article-title":"IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:21:18Z","timestamp":1718986878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":50,"alternative-id":["S0145212617300073"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}